MedTrace Logo

Late Effects and HRQoL in Survivors of Allo-HSCT - a Cross Sectional Study

NCT06277479 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1262

Last updated 2025-12-18

No results posted yet for this study

Summary

The cross-sectional study aims to describe the burden of late effects and survivorship-specific health-related quality of life in a nationwide cohort of patients treated with allo-HSCT in Denmark. Further, identify demographic, medical or personal factors associated with better self-reported health and quality of life.

Conditions

  • Hematological Diseases

Sponsors & Collaborators

  • Danish Cancer Society

    collaborator OTHER

  • Rigshospitalet, Denmark

    lead OTHER

Principal Investigators

  • Mette Schaufuss Engedal, MSc · Rigshospitalet, Denmark

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-25
Primary Completion
2025-12-01
Completion
2025-12-01

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06277479 on ClinicalTrials.gov